Sorafenib: from literature to clinical practice
- Authors: Di Marco, V; De Vita, F; Koskinas, J; Semela, D; Toniutto, P; Verslype, C
- Publication year: 2013
- Type: Articolo in rivista (Articolo in rivista)
- Key words: adverse events; clinical practice; observational studies; randomized clinical trials; sorafenib; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Molecular Targeted Therapy; Translational Medical Research
- OA Link: http://hdl.handle.net/10447/88483
Abstract
Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. The approval of sorafenib for this indication was grounded on the efficacy and the safety results reported by two international randomized, controlled trials, the SHARP and the Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in clinical practice are addressed by several field-practice experiences, including the multinational GIDEON study and the SOFIA study. Finally, further research on sorafenib is ongoing to optimize the use of this molecule. This review aims to provide an overview of the most relevant clinical data on the efficacy and the safety of sorafenib in patients with HCC.